Our technology allows a highly controlled administration of radionuclides directly into the tumoral mass.
It achieves the highest efficacy where it is needed, while at the same time minimizing the risk of unwanted side effects, both locally and in the entire patient’s body.
Administration device engineered to guarantee a precise delivery of the required dose of energy where it is needed, thus overcoming some disadvantages of external beam radiation therapy (EBRT).
The applications of this β-emitting radiotherapy platform is currently being developed to treat unresectable primary hepatocellular carcinoma (HCC).
Additional applications for other loco-regional treatments are being researched.